// App-Quantinova.ai

31 : STAT3 Inhibition Synergizes with BCR-ABL1 Inhibition to Overcome Kinase-Independent TKI Resistance in Chronic Myeloid Leukemia (CML)

Researchers

Presenter

  • Ira L Kraft

Principal Investigators

  • Brent DG Page

  • Thomas -Hare

  • Michael W Deininger

  • David J Anderson

  • Zhimin Gu

  • Jamshid S Khorashad

  • Anthony D Pomicter

  • Kimberly R Reynolds

  • Matthew S Zabriskie

  • Richard Moriggl

  • Patrick T Gunning

Medical Centers

  • Department of Chemistry, University of Toronto Mississauga, Mississauga, ON, Canada

  • Ludwig Boltzmann Institute for Cancer Research, Vienna, Austria

  • Huntsman Cancer Institute at the University of Utah, Salt Lake City, UT

Locations

  • United States

  • Canada

  • Austria

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Chronic Myelogenous Leukemia

Biomarkers

  • Breakpoint Cluster Region

  • Cluster of Differentiation 34

  • Cluster of Differentiation 38

Drug/Treatment

  • Imatinib

  • IkT001

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved